Novelix Pharmaceuticals Ltd (TRIMURTHI) is currently trading at 69.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Novelix Pharmaceuticals is a small-cap Indian company that manufactures and trades active pharmaceutical ingredients (APIs) and related intermediates; the company renamed itself from Trimurthi Limited to Novelix Pharmaceuticals in 2025 after a strategic pivot and promoter change to focus on pharmaceuticals and healthcare research, analytics and technology. Financials for the quarter ended 30 June 2026 show total revenue of Rs. 3,691.51 lakhs and profit before tax of Rs. 111.53 lakhs; this represents a strong sequential revenue increase from Rs. 2,519.36 lakhs in the prior quarter and a large year-on-year profitability improvement compared with June 2025. Operational expense profile is dominated by purchases of stock-in-trade at Rs. 3,193.39 lakhs and a notable inventory movement of Rs. 292.95 lakhs, indicating trading/working-capital intensive operations; reported EBITDA-like profit before tax is modest, suggesting thin operating leverage in current business mix. Corporate governance and formal approvals are current: the June quarter results were reviewed by the Audit Committee and approved by the Board on 13 August 2026, signed by Whole-time Director Venkateshwarlu Pulluru, and accompanied by a limited review report from the external auditors, providing transparency on reported numbers.

Over the past 52 weeks, Novelix Pharmaceuticals Ltd has traded between a low of ₹49.01 and a high of ₹92.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Novelix Pharmaceuticals Ltd has a market capitalization of approximately 190.81. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Novelix Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -74.83 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 190.81 Cr, Novelix Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Novelix Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Novelix Pharmaceuticals Ltd is -74.83. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.